Edwards Lifesciences stock trades at USD 88.25

Published on 09/19/2026 at 12:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Edwards Lifesciences stock traded at USD 88.25 on September 18, 2026, while the market cap stood at USD 50.87 billion. The latest cited quarter showed USD 1.53 billion in sales.

Fotorealistisches Katheterlabor mit Chirurgenteam bei minimalinvasivem Herzeingriff — Edwards Lifesciences Herzklappen-OP US28176E1082 im Katheterlabor mit Fluoroskopie-Bildschirmen und Chirurgenteam in Aktion, Illustration mit AI erstellt.

Edwards Lifesciences stock (US28176E1082) traded at USD 88.25 on September 18, 2026, while the company's market cap was reported at USD 50.87 billion on the same date. The latest cited quarter showed sales of USD 1.53 billion, up 11.9 percent year on year, and the stock was assessed at USD 88.94 resistance in a September 19, 2026, setup note.

Sales and cash flow

According to GlobeNewswire on September 18, 2026, Edwards Lifesciences reported second-quarter 2025 sales of USD 1.53 billion, an increase of 11.9 percent. The same report cited structural heart and valve therapies as the demand backdrop.

Yahoo Finance also said on September 18, 2026, that Edwards Lifesciences' narrative projects USD 8.5 billion in revenue and USD 2.2 billion in earnings by 2029, implying 9.3 percent yearly revenue growth from that base. In the same flow, the forecast work put latest twelve month free cash flow at about USD 1.40 billion.

Chart levels matter

According to Stock Traders Daily on September 19, 2026, Edwards Lifesciences showed resistance at USD 88.94, with a breakout trigger at USD 88.94 and a long-term level at USD 94.88. The same note listed an entry zone at USD 82.86 and a stop loss at USD 82.62.

That leaves the stock close to the resistance area and above the reported entry zone, so the next move is more about whether buyers can clear USD 88.94 than about a broad rerating.

Market value first

Edwards Lifesciences stock closed at USD 88.25 on September 18, 2026, with a market cap of USD 50.87 billion. The quoted market value and the recent sales figure frame the stock better than a pure headline move.